Find a Clinical Trial

Filter

Showing 1 - 6 out of 6

Dompe' Reparixin study

A multinational, multicentre, randomised, doubleblinded, placebo-controlled, parallel-group phase III trial Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19.

COVID-19

All genders

18+

Recruiting now

Department of Medicine, Division of Geographic Medicine + Infectious Diseases

Learn more

Moderna mRNA 1273 study

A Phase 2/3, Two-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Children 6 Months to Less Than 12 Years of Age

COVID-19

All genders

0-12

Recruiting now

Department of Medicine, Division of Geographic Medicine + Infectious Diseases

Learn more

A Long COVID-19 Observational Pilot Study Using Wearable Devices

Detection and Risk Assessment in Post COVID-19 Infection – A Long COVID-19 Observational Pilot Study

COVID-19

All genders

18+

Recruiting now

Department of Medicine, Division of Geographic Medicine + Infectious Diseases

Learn more

COVID-19 Survivors Registry

National COVID-19 Survivors Registry

COVID-19

All genders

18+

Recruiting now

Department of Medicine, Division of Geographic Medicine + Infectious Diseases

Learn more

RECOVER VITAL

RECOVER‐VITAL: A Platform Protocol for Evaluation of
Interventions for Viral Persistence, Viral Reactivation,
and Immune Dysregulation in Post‐Acute Sequelae of
SARS‐CoV‐2 Infection (PASC)

COVID-19

All genders

18+

Recruiting now

Department of Medicine, Division of Geographic Medicine + Infectious Diseases

Learn more

COVID-19 Biorepository study

Tufts Medical Center and Tufts University COVID-19 Biorepository Study

COVID-19

All genders

18+

Recruiting now

Department of Medicine, Division of Geographic Medicine + Infectious Diseases

Learn more

Filter

A multinational, multicentre, randomised, doubleblinded, placebo-controlled, parallel-group phase III trial Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19.

A Phase 2/3, Two-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Children 6 Months to Less Than 12 Years of Age

Detection and Risk Assessment in Post COVID-19 Infection – A Long COVID-19 Observational Pilot Study

National COVID-19 Survivors Registry

RECOVER‐VITAL: A Platform Protocol for Evaluation of Interventions for Viral Persistence, Viral Reactivation, and Immune Dysregulation in Post‐Acute Sequelae of SARS‐CoV‐2 Infection (PASC)

Tufts Medical Center and Tufts University COVID-19 Biorepository Study

RECOVER‐VITAL: A Platform Protocol for Evaluation of
Interventions for Viral Persistence, Viral Reactivation,
and Immune Dysregulation in Post‐Acute Sequelae of
SARS‐CoV‐2 Infection (PASC)